03/16/2021
Exciting news for B.C. Neuroendocrine patients!
LUTATHERA® Funded in British Columbia
CNETS is pleased to announce that BC Cancer will now reimburse LUTATHERA® for the approved indication.
The BC Cancer Benefit Drug List, published in March 2021, approved indication for LUTATHERA®:
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours.
For more information: BC Cancer Benefit Drug List
BC Cancer also provided the Protocol Summary for Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours.
For more information: BC Cancer Protocol Summary
CNETS will continue provide updates on LUTATHERA® funding in other provinces, and information on PRRT on our website, please visit:
PRRT INFORMATION
CNETS | 1-844-628-6788 | info@cnets.ca | www.cnets.ca
STAY CONNECTED
Facebook Twitter YouTube
CNETS Canada
333 Pitt Street
Suite 102
Cornwall, Ontario K6J 3R1 Canada
Education Days NET Presentations Webinars Conferences NET Guidelines NET Reference Guide CNETS One Pager Nutrition Support Group Meetings, CNETS Fundraisers, Patient Education Days, Awareness Campaigns and more. NET Cancer Day, NET Awareness Videos, Press Releases HOW WE HELP Donated to NET cancer r...